Patents by Inventor Ralph Weissleder

Ralph Weissleder has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190113508
    Abstract: The present invention provides novel compositions of binding moiety-nanoparticle conjugates, aggregates of these conjugates, and novel methods of using these conjugates, and aggregates. The nanoparticles in these conjugates can be magnetic metal oxides, either monodisperse or polydisperse. Binding moieties can be, e.g., oligonucleotides, polypeptides, or polysaccharides. Oligonucleotide sequences are linked to either non-polymer surface functionalized metal oxides or with functionalized polymers associated with the metal oxides. The novel compositions can be used in assays for detecting target molecules, such as nucleic acids and proteins, in vitro or as magnetic resonance (MR) contrast agents to detect target molecules in living organisms.
    Type: Application
    Filed: May 8, 2018
    Publication date: April 18, 2019
    Inventors: Lee Josephson, Ralph Weissleder, J. Manuel Perez
  • Publication number: 20190054184
    Abstract: Compositions comprising a macrophage-targeted carrier and one or more therapeutic agents that modulate cardiac conductance, and methods of using the same for treating subjects with cardiac rhythm disorders, e.g., bradycardia or tachycardia.
    Type: Application
    Filed: February 13, 2017
    Publication date: February 21, 2019
    Inventors: Maarten Hulsmans, Matthias Nahrendorf, Ralph Weissleder
  • Publication number: 20190040021
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Application
    Filed: February 26, 2018
    Publication date: February 7, 2019
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • Patent number: 10179775
    Abstract: This disclosure relates to trans-cyclooctene compounds and methods of using the same in bioorthogonal labeling experiments.
    Type: Grant
    Filed: August 11, 2015
    Date of Patent: January 15, 2019
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Balazs R. Varga, Ralph Weissleder
  • Publication number: 20180361000
    Abstract: This disclosure relates to specific nanometer-sized nanoparticles made from unmodified dextran (DNPs), DNP conjugates, and related compositions and methods of use.
    Type: Application
    Filed: December 9, 2016
    Publication date: December 20, 2018
    Applicant: The General Hospital Corporation
    Inventors: Ralph Weissleder, Edmund J. Keliher, Matthias Nahrendorf
  • Patent number: 10151753
    Abstract: In one aspect, a system for isolating particles includes a first array of magnets, a second array of magnets arranged generally in parallel with and spaced apart from the first array of magnets, and a micro fluidic device. The micro fluidic device includes a substrate, an inlet arranged on the substrate and configured to receive a fluid sample, an outlet arranged on the substrate, a first region of the substrate including a channel connected to the inlet, where the first region of the substrate is arranged to sandwich the channel between the first and second arrays of magnets.
    Type: Grant
    Filed: December 17, 2014
    Date of Patent: December 11, 2018
    Assignee: The General Hospital Corporation
    Inventors: Hakho Lee, Ralph Weissleder, Kyungheon Lee, Jun Song
  • Patent number: 10124077
    Abstract: Described herein are compositions and methods for cancer cell biomarkers, such as pancreatic ductal adenocarcinoma (PDAC) cell biomarkers, and binding molecules for diagnosis and treatment of cancer, e.g., PDAC. Methods of identifying “accessible” proteomes are disclosed for identifying cancer biomarkers, such as plectin-1, a PDAC biomarker. Additionally, imaging compositions are provided comprising magnetofluorescent nanoparticles conjugated to peptide ligands for identifying PDACs.
    Type: Grant
    Filed: June 8, 2016
    Date of Patent: November 13, 2018
    Assignee: The General Hospital Corporation
    Inventors: Kimberly Kelly, Ralph Weissleder, Nabeel Bardeesy
  • Patent number: 10117954
    Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.
    Type: Grant
    Filed: April 28, 2017
    Date of Patent: November 6, 2018
    Assignee: The General Hospital Corporation
    Inventors: Thomas Reiner, Edmund J. Keliher, Ralph Weissleder
  • Patent number: 10111971
    Abstract: A magnetic nanoparticle includes a magnetic core and a superparamagnetic outer shell, in which the outer shell enhances magnetic properties of the nanoparticle. The enhanced magnetic properties of the magnetic nanoparticle allow for highly sensitive detection as well as diminished non-specific aggregation of nanoparticles.
    Type: Grant
    Filed: April 14, 2017
    Date of Patent: October 30, 2018
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Hakho Lee, Tae-Jong Yoon
  • Patent number: 10012589
    Abstract: The disclosure features systems and methods for measuring and diagnosing target constituents bound to labeling particles in a sample. The systems include a radiation source, a sample holder, a detector configured to obtain one or more diffraction patterns of the sample each including information corresponding to optical properties of sample constituents, and an electronic processor configured to, for each of the one or more diffraction patterns: (a) analyze the diffraction pattern to obtain amplitude information and phase information corresponding to the sample constituents; (b) identify one or more particle-bound target sample constituents based on at least one of the amplitude information and the phase information; and (c) determine an amount of at least one of the particle-bound target sample constituents in the sample based on at least one of the amplitude information and the phase information.
    Type: Grant
    Filed: August 18, 2014
    Date of Patent: July 3, 2018
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Hakho Lee, Hyungsoon Im, Cesar Castro
  • Patent number: 9999689
    Abstract: The present disclosure provides compositions and methods based on peptide-detectable agent conjugates that are useful for imaging beta cell mass.
    Type: Grant
    Filed: March 21, 2016
    Date of Patent: June 19, 2018
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Thomas Reiner, Edmund J. Keliher
  • Patent number: 9958416
    Abstract: Determining a presence of a target analyte in a fluid sample includes mixing multiple magnetic particles with the fluid sample, in which the magnetic particles are each bound to one or more binding moieties that specifically bind to the target analyte, flowing the fluid sample containing the magnetic particles through a fluidic channel, exposing the fluid sample in the fluidic channel to a magnetic field, measuring a signal from a Hall effect sensor while the fluid sample flows through the fluidic channel, and determining whether the target analyte is present in the fluid sample when the measured signal is in a first range of values.
    Type: Grant
    Filed: November 21, 2012
    Date of Patent: May 1, 2018
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Hakho Lee, David Issadore
  • Patent number: 9902705
    Abstract: The present application relates to functionalized 1,2,4,5-tetrazine compounds. The compounds are useful in compositions and methods using bioorthogonal inverse electron demand Diels-Alder cycloaddition reactions for the rapid and specific covalent delivery of a “payload” to a ligand bound to a biological target.
    Type: Grant
    Filed: March 14, 2013
    Date of Patent: February 27, 2018
    Assignee: The General Hospital Corporation
    Inventors: Scott A. Hilderbrand, Neal K. Devaraj, Ralph Weissleder, Mark R. Karver
  • Patent number: 9874564
    Abstract: A portable magnetic resonance system includes a permanent magnet, a nuclear magnetic resonance probe, and control electronics. The control electronics are configured to transmit to the probe a magnetic resonance excitation signal having an excitation frequency f, receive from the probe a magnetic resonance measurement signal, detect in the magnetic resonance measurement signal a magnetic resonance frequency f0, and automatically adjust the excitation frequency f until the difference between the excitation frequency and the magnetic resonance frequency is approximately equal to a target offset.
    Type: Grant
    Filed: March 21, 2012
    Date of Patent: January 23, 2018
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Hakho Lee, David Issadore
  • Publication number: 20180015186
    Abstract: This document relates to compounds useful for targeting PARP1. Also provided herein are methods for using such compounds to detect and image cancer cells.
    Type: Application
    Filed: April 28, 2017
    Publication date: January 18, 2018
    Inventors: Thomas Reiner, Edmund J. Keliher, Ralph Weissleder
  • Patent number: 9869619
    Abstract: A magnetic device includes a substrate and an array including a plurality of magnetic particles, in which a magnetic dipole moment direction of each magnetic particle in a majority of the magnetic particles in the array alternates with respect to a magnetic dipole direction of a directly adjacent magnetic particle or directly adjacent magnetic particles in the array.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: January 16, 2018
    Assignee: The General Hospital Corporation
    Inventors: Ralph Weissleder, Hakho Lee, David Issadore
  • Publication number: 20170368202
    Abstract: The present invention provides methods and compositions based on optical sensor conjugates that are useful for detecting reactive oxygen, reactive nitrogen, or both species that are a direct result of inflammation caused by tissue damage.
    Type: Application
    Filed: May 1, 2017
    Publication date: December 28, 2017
    Inventors: Scott A. Hilderbrand, Ralph Weissleder, Peter Panizzi, Jason R. McCarthy
  • Publication number: 20170340736
    Abstract: Provided herein are compositions containing photoactivatable caged tamoxifen and tamoxifen derivative molecules. Also provided are kits containing one of these compositions and a light source. Also provided are methods of optically inducing nuclear translocation of a fusion protein containing a mammalian estrogen receptor ligand binding domain in a eukaryotic cell and methods of optically inducing recombination in a eukaryotic cell that include contacting a eukaryotic cell with at least one of these compositions. Also provided are methods of treating breast cancer in a subject that include administering a photoactivatable caged tamoxifen or tamoxifen derivative molecule to a subject having breast cancer.
    Type: Application
    Filed: May 25, 2017
    Publication date: November 30, 2017
    Inventors: Xin Lu, Sarit S. Agasti, Ronald A. DePinho, Ralph Weissleder
  • Publication number: 20170275669
    Abstract: Described herein are methods, compositions, kits and systems for multiplexed detection of target molecules from a sample. In some embodiments, the methods, compositions, kits and systems can be used to perform multiplexed protein analysis of a sample (e.g., a sample comprising a small number of cells or a single-cell sample). In some embodiments, the same sample subjected to a multiplexed protein analysis using the methods, compositions, kits and systems described herein can also be subjected to a nucleic acid (e.g., RNAs, microRNAs, and/or DNA) analysis, thereby creating an integrated expression profiling from a limited amount of sample.
    Type: Application
    Filed: June 3, 2014
    Publication date: September 28, 2017
    Inventors: Ralph WEISSLEDER, Sarit S. AGASTI, Vanessa M. PETERSON, Adeeti ULLAL
  • Publication number: 20170233365
    Abstract: This disclosure relates to trans-cyclooctene compounds and methods of using the same in bioorthogonal labeling experiments.
    Type: Application
    Filed: August 11, 2015
    Publication date: August 17, 2017
    Inventors: Scott A. Hilderbrand, Balazs R. Varga, Ralph Weissleder